NASDAQ:OCDX

Ortho Customers Rank Company No. 1 in Service and Support for Sixth Consecutive Year

Company receives top customer rating across six categories in the 2021 IMV ServiceTrak™ Awards RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) today announced that for the sixth consecutive year its Ortho Care™ Service and Support program was ...

2021-09-27 22:00 4691

Ortho Clinical Diagnostics Announces Launch of New ISXM Capabilities

New Menu Capability Now Available on VISION and VISION MAX Analyzers Increases Confidence in Blood Transfusion-Related Test Results RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics  (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, ...

2021-09-27 20:00 2757

Ortho Clinical Diagnostics Expands COVID-19 Test Offerings with Emergency Use Authorization (EUA) of Total Nucleocapsid Antibody Test

 -- Ortho's new VITROS® Anti-SARS-CoV-2 Total N test detects the individual's immune response to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent or prior COVID-19 infection.  -- Ortho is the first company to have an EUA for both a quantitative IgG a...

2021-08-05 21:05 28148

ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in Canada

RARITAN, N.J., July 26, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care...

2021-07-26 21:00 5239

Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Critical Care Blood Testing Menu

RARITAN, N.J., July 22, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics  (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its VITROS® Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho's VITROS® Critical Care menu, is now ...

2021-07-22 21:00 7576

Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization

- Ortho's new VITROS® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians and public health leaders a standard tool to measure antibody response to SARS-CoV-2 - Ortho is ...

2021-07-10 03:33 29681

Ortho Clinical Diagnostics Announces Partnership With Thermo Fisher Scientific

Introducing VITROS® QC Solutions, taking your lab to the next level with Thermo Scientific™ MAS™ Quality Controls RARITAN, N.J., July 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics  (Nasdaq: OCDX), one of the world's largest pure-play, in-vitro diagnostics (IVD) companies, today announced its...

2021-07-07 21:00 30593

ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in the United States and Puerto Rico

RARITAN, N.J., June 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care ...

2021-06-07 21:00 5898

Ortho Clinical Diagnostics Simultaneously Launches First Quantitative COVID-19 IgG Spike Antibody Test As Well As A Nucleocapsid Antibody Test to Help Differentiate Cause of Antibody Response

- Ortho is the only company that offers laboratories in the U.S. a quantitative test in combination with a nucleocapsid test - Both new antibody tests help health care teams differentiate the cause of antibodies against SARS-CoV-2 - Ortho's new VITROS® Anti-SARS-CoV-2 IgG Quantitative Antibody t...

2021-05-22 05:22 9302

Ortho Clinical Diagnostics Launches Quantitative COVID-19 IgG Antibody Test with CE Mark

- Ortho's VITROS® Anti-SARS-CoV-2 IgG Quantitative Antibody test is traceable to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which is developed to facilitate the standardization of SARS-CoV-2 serological methods - The test gives clinicians and public health leaders a standa...

2021-05-05 20:00 2900

Global Transfusion Medicine Leader Ortho Clinical Diagnostics Launches Next Gen ORTHO VISION® Swift Platform

ORTHO VISION is the leading choice for blood banks RARITAN, N.J., May 3, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics  (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced the availability of enhanced ORTHO VISION® Swift and ORTHO VISION® Max Swi...

2021-05-03 20:00 3429

Ortho Clinical Diagnostics Recognized With Prestigious Edison Award for Highly Accurate COVID-19 Solutions Capable of Mass-Scale Testing

Silver Award Recognizes Antibody and Antigen Tests RARITAN, N.J., April 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics  (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious silver 2021 Edison Award for its VITROS® C...

2021-04-27 05:16 1944

Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media

RARITAN, N.J., April 13, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics  (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received CE Marking for its VITROS® SARS-CoV-2 Antigen Test, initially launched in October 2020. The CE Mark allows for ...

2021-04-13 21:00 3320

Ortho Announces Plans to Accelerate COVID-19 Antigen and Antibody Test Development Through New Contract with BARDA and the Department of Defense

RARITAN, N.J., April 1, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play IVD companies, today announced that through its continued partnership with the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of Def...

2021-04-01 08:03 1545

Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data

RARITAN, N.J., March 23, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics  (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received authorization from the U.S. Food and Drug Administration to update key claims for the VITROS® SARS-CoV-2 Antige...

2021-03-23 20:00 2814

Ortho's New COVID-19 Total and IgG Antibody Tests Receive CE Mark for Semi-Quantitative Results

- Ortho's new VITROS® Anti-SARS-CoV-2 Total 2 Antibody assay and VITROS® Anti-SARS-CoV-2 IgG 2 Antibody assay receive CE Mark - Both tests can aid in identifying individuals with an adaptive immune response (acquired naturally or through vaccination) to SARS-CoV-2 - These new anti-SARS-CoV-2 ant...

2021-03-08 21:00 3051

Ortho Clinical Diagnostics Announces Closing of Full Over-Allotment Option from Initial Public Offering

RARITAN, N.J., Feb. 5, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the cl...

2021-02-05 06:40 6569

Ortho Clinical Diagnostics Announces Pricing of Initial Public Offering

RARITAN, N.J., Jan. 28, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the pricing of its i...

2021-01-28 11:38 6966